Description
Description: This assay employs a two-site sandwich ELISA to quantitate FZD9 in samples. An antibody specific for FZD9 has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any FZD9 present is bound by the immobilized antibody. After removing any unbound substances, a biotin-conjugated antibody specific for FZD9 is added to the wells. After washing, Streptavidin conjugated Horseradish Peroxidase (HRP) is added to the wells. Following a wash to remove any unbound avidin-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of FZD9 bound in the initial step. The color development is stopped and the intensity of the color is measured.
Overview: The FZD9 gene is located within the Williams syndrome common deletion region of chromosome 7, and heterozygous deletion of the FZD9 gene may contribute to the Williams syndrome phenotype. FZD9 is expressed predominantly in brain, testis, eye, skeletal muscle, and kidney. In mouse, the wg-homologous Wnt1 gene is involved in early development of a large domain of the central nervous system encompassing much of the midbrain and rostral metencephalon.The potential function of FZD9 in transmitting a Wnt protein signal in the human brain and other tissues suggested to Wang et al. (1997) that heterozygous deletion of the FZD9 gene could contribute to the Williams syndrome phenotype